Remission Evaluation of a Metabolic Intervention in Type 2 Diabetes With Forxiga
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 154 participants.
Also called NCT02561130
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 154 participants
- Registry
-
NCT02561130
-
- Other papers using this trial's data
- Remission of Type 2 Diabetes Following a Short-term Intervention With Insulin Glargine, Metformin, and Dapagliflozin
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Canada
- Registry status
- Completed
Technical summary
Registry record NCT02561130. Randomized; no masking; primary purpose treatment. Start 2015-12 (actual); primary completion 2017-07 (actual). Results posted on 2020-11-24.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Remission Evaluation of a Metabolic Intervention in Type 2 Diabetes With Forxiga
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- insulin glargine
- Intervention (Drug)
- metformin
- Intervention (Drug)
- Forxiga
- Intervention (Behavioral)
- Lifestyle therapy
- Lead sponsor
- Population Health Research Institute
- Collaborator
- AstraZeneca
Record details
- Record id
cardio:ct-nct02561130- Content hash
7e452af9e88b4e47501bfa4925d41869fc608d15d6166b10d639b0401a004618